Short Interest in Fresenius SE & Co. (OTCMKTS:FSNUY) Declines By 96.9%

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 32,056 shares, a decline of 96.9% from the August 15th total of 1,029,832 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 141,927 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Several brokerages have recently issued reports on FSNUY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Fresenius SE & Co. presently has a consensus rating of “Buy”.

Fresenius SE & Co. Price Performance

Shares of Fresenius SE & Co. stock traded up $0.09 on Friday, hitting $13.09. The company had a trading volume of 68,870 shares, compared to its average volume of 77,886. The business has a 50-day simple moving average of $12.94 and a 200-day simple moving average of $12.53. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.27 and a quick ratio of 0.98. The company has a market cap of $29.49 billion, a PE ratio of 16.57 and a beta of 0.62. Fresenius SE & Co. has a 52 week low of $10.33 and a 52 week high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY) last announced its earnings results on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.33% and a net margin of 6.67%. Research analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care company headquartered in Bad Homburg. The company develops and provides products and services for hospitals, outpatient care, and patients with chronic or complex medical conditions.

Its principal operating businesses are Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies medicines, clinical nutrition products, infusion and transfusion technologies, and related devices and services. Fresenius Helios operates hospitals and outpatient facilities, primarily in Germany and Spain, providing a broad range of medical and surgical care.

Fresenius traces its origins to a pharmacy established by the Fresenius family in Frankfurt in the 15th century and has evolved into an international health care group serving markets across Europe, North America, Latin America, Asia, and other regions.